Compare Agnico Eagle Mines Ltd (AEM) vs TG Therapeutics Inc (TGTX) Price & Performance

AEM trades at $185.71, up 2.9% over the past day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $11.91 billion in 2025, with a net income margin of 40.44%, and maintains a solid balance sheet with total assets of $29.99 billion. Recent news highlights record free cash flow and a 20-30% gold production growth target through organic expansion.

The stock offers upside to the consensus price target of $219.63, supported by strong profitability and analyst optimism, but faces risks from rising costs and gold price volatility. With 67.74% of analysts rating it a buy, AEM remains a compelling play on gold, though investors should monitor cost pressures and production guidance.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.